What is the 13F Pro Quality Score for COCP?

13F Pro ranks Cocrystal Pharma, Inc. (COCP) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View COCP's current score at https://13fpro.ai/research/COCP (free sign-up required for the full ranking).

Where does 13F Pro source COCP data?

All Cocrystal Pharma, Inc. fundamentals and ownership data come directly from SEC EDGAR. Cocrystal Pharma, Inc. files with the SEC under CIK 1412486. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is COCP in?

Cocrystal Pharma, Inc. (COCP) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is COCP research updated on 13F Pro?

COCP's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Cocrystal Pharma, Inc.(COCP)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1412486 COCP stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Limited institutional coverage

Quality rankings require at least 50 unique 13-F institutional holders to ensure peer comparisons are meaningful. Only 26 institutional filers currently hold this stock.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

COCP Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Cocrystal Pharma, Inc. (COCP), a Healthcare sector company. COCP is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least 50 unique 13-f institutional holders to ensure peer comparisons are meaningful. only 26 institutional filers currently hold this stock. Based on the latest XBRL financial filings (Q1 2026), Cocrystal Pharma, Inc. reports quarterly revenue of $225.0K, net income of $-2.3M, free cash flow of $-2.3M. Top institutional holders of COCP by reported 13-F value include VANGUARD CAPITAL MANAGEMENT, RENAISSANCE TECHNOLOGIES, GEODE CAPITAL MANAGEMENT,, based on the most recent SEC filings. COCP trades on the Nasdaq exchange and files with the SEC under CIK 1412486. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate COCP daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Cocrystal Pharma, Inc. directly from SEC EDGAR.

Revenue

Q1 2026

$225.0K

Net Income

Q1 2026

$-2.3M

Free Cash Flow

Q1 2026

$-2.3M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

—FY 2025

FY22 —FY23 —FY24 —FY25 —

Net Income

+49.5% YoY

$-8.8MFY 2025

FY22 $-38.8MFY23 $-18.0MFY24 $-17.5MFY25 $-8.8M

Operating Income

+49.6% YoY

$-9.0MFY 2025

FY22 $-38.8MFY23 $-18.6MFY24 $-17.9MFY25 $-9.0M

EPS (Diluted)

+54.7% YoY

$-0.78FY 2025

FY22 $-4.77FY23 $-1.87FY24 $-1.72FY25 $-0.78

Total Assets

-27.8% YoY

$9.7MFY 2025

FY22 $40.8MFY23 $31.3MFY24 $13.5MFY25 $9.7M

Op. Cash Flow

+50.3% YoY

$-8.2MFY 2025

FY22 $-21.4MFY23 $-14.7MFY24 $-16.5MFY25 $-8.2M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2020	FY 2019
Revenue	—	—	—	—	$2.0M -69.3%	$6.6M
Net Income	$-8.8M +49.5%	$-17.5M +2.7%	$-18.0M +53.7%	$-38.8M -302.5%	$-9.6M +80.0%	$-48.2M
Operating Income	$-9.0M +49.6%	$-17.9M +3.7%	$-18.6M +52.2%	$-38.8M -305.1%	$-9.6M +80.2%	$-48.4M
EPS (Diluted)	$-0.78 +54.7%	$-1.72 +8.0%	$-1.87 +60.8%	$-4.77	—	—
Total Assets	$9.7M -27.8%	$13.5M -57.0%	$31.3M -23.5%	$40.8M -24.7%	$54.2M +90.1%	$28.5M
Operating Cash Flow	$-8.2M +50.3%	$-16.5M -12.4%	$-14.7M +31.6%	$-21.4M -118.1%	$-9.8M -528.9%	$-1.6M

AI Insight: COCP Financial Trends

Cocrystal is burning cash at a decelerating rate, but equity erosion and lack of revenue remain critical red flags.

• Net income loss narrowed from $5M in Q2 2024 to $2M in Q1 2026; operating cash burn halved over same period.

• Q1 2026 marked first recorded revenue quarter ($0M), signaling commercialization attempt or milestone reporting.

• Shareholder equity collapsed 76% from $17M (Q2 2024) to $4M (Q1 2026), driven by cumulative losses.

⚠ Operating cash flow stabilized at $1M–$2M in recent quarters but company remains unprofitable with minimal equity cushion.

⚠ Zero reported revenue through Q1 2026 despite operating losses; sustainability of remaining capital unclear.

AI Insight: COCP Ratio Trends

Cocrystal remains unprofitable across all measured periods; insufficient data to assess operational trends.

• ROA improved from -99.9% in Q4 2025 to -78.5% in Q3 2025, suggesting intra-year volatility rather than sustained recovery.

• ROE consistently negative throughout 2024–2025 (range: -106.9% to -155.5%), indicating persistent losses eroding shareholder value.

⚠ OpMargin, NPM, ROIC, and D/E all missing across all quarters—limits ability to assess operational efficiency, leverage, or margin trajectory.

⚠ ROA deteriorated sharply to -99.9% in Q4 2025, worst level since Q2 2024; requires clarity on underlying losses.

Get alerted when COCP's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Cocrystal Pharma, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of COCP

VANGUARD CAPITAL MANAGEMENT LLC
$242.4K239,971 sh
RENAISSANCE TECHNOLOGIES LLC
$125.2K123,928 sh
GEODE CAPITAL MANAGEMENT, LLC
$91.1K90,231 sh
BlackRock, Inc.
$74.5K73,746 sh
T3 Companies, LLC
$52.0K51,500 sh
XTX Topco Ltd
$36.4K36,031 sh
Neuberger Berman Group LLC
$32.2K31,886 sh
VANGUARD FIDUCIARY TRUST CO
$24.3K24,016 sh
STATE STREET CORP
$20.7K20,543 sh
TWO SIGMA SECURITIES, LLC
$15.4K15,255 sh

Fund	Value	Shares
VANGUARD CAPITAL MANAGEMENT LLC	$242.4K	239,971
RENAISSANCE TECHNOLOGIES LLC	$125.2K	123,928
GEODE CAPITAL MANAGEMENT, LLC	$91.1K	90,231
BlackRock, Inc.	$74.5K	73,746
T3 Companies, LLC	$52.0K	51,500
XTX Topco Ltd	$36.4K	36,031
Neuberger Berman Group LLC	$32.2K	31,886
VANGUARD FIDUCIARY TRUST CO	$24.3K	24,016
STATE STREET CORP	$20.7K	20,543
TWO SIGMA SECURITIES, LLC	$15.4K	15,255

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put COCP on your watchlist

Track score changes the day Cocrystal Pharma, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is COCP a good stock to buy?

13F Pro's AI-powered analysis of Cocrystal Pharma, Inc. (COCP) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for COCP are available on the COCP stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own COCP?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling COCP. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Cocrystal Pharma, Inc.'s investment landscape.